Victor Miller - Orgenesis Chief Officer

Executive

Victor Miller is Chief Officer of Orgenesis
Age 54
Phone480 659 6404
Webhttps://orgenesis.com

Victor Miller Latest Insider Activity

Tracking and analyzing the buying and selling activities of Victor Miller against Orgenesis otc stock is an integral part of due diligence when investing in Orgenesis. Victor Miller insider activity provides valuable insight into whether Orgenesis is net buyers or sellers over its current business cycle. Note, Orgenesis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Orgenesis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Orgenesis Management Efficiency

The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.
Orgenesis currently holds 22.62 M in liabilities with Debt to Equity (D/E) ratio of 0.64, which is about average as compared to similar companies. Orgenesis has a current ratio of 1.54, which is within standard range for the sector. Debt can assist Orgenesis until it has trouble settling it off, either with new capital or with free cash flow. So, Orgenesis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orgenesis sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orgenesis to invest in growth at high rates of return. When we think about Orgenesis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

MD FACCDesign Therapeutics
56
Joshua JDAN2 Therapeutics
47
Jannik AndersenTango Therapeutics
N/A
MD MBAIndaptus Therapeutics
58
Julie CarreteroTango Therapeutics
53
Tariq AhmedAchilles Therapeutics PLC
N/A
Edward SamuelAchilles Therapeutics PLC
N/A
Mustapha ParekhDesign Therapeutics
N/A
Johannes MDLixte Biotechnology Holdings
69
Michael DeperroRezolute
N/A
Stephen YuAerovate Therapeutics
N/A
MaryAlice JDAcrivon Therapeutics, Common
51
John MSTango Therapeutics
N/A
Marinus VerwijsAerovate Therapeutics
48
Shree PatelAchilles Therapeutics PLC
N/A
Erin OBoyleRezolute
N/A
Jennifer HuberAN2 Therapeutics
N/A
Gopal MBBSRezolute
N/A
Lee SternAchilles Therapeutics PLC
N/A
Ami KnoeflerAdagene
N/A
Susan FischerAerovate Therapeutics
N/A
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. Orgenesis [ORGS] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Orgenesis Leadership Team

Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Victor Miller, Chief Officer
Osher Rheinisch, General Officer
Neil CPA, S CFO
Shimon Hassin, Chief Officer
Efrat Kunik, Chief Officer
Pierre Lammeretz, Interim Officer
Evan Fishman, Chief Officer
Joseph Carpinelli, Chief Octomera
Dan Slonim, COO Israel
Vered MSc, CEO Board
Pr Ferber, Founder Officer
Vincent Vandamme, VP Strategy

Orgenesis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Orgenesis OTC Stock

If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets